'Not FDA-approved' denials
The plan says the drug or its specific use isn't FDA-approved. Distinct from 'experimental' — and appealable when off-label use is medically supported.
What this denial means
A not-FDA-approved denial (which may be associated with CARC 114 or 188) means the plan classified the drug, dose, or requested indication as outside the approval basis it applied. Verify the exact reason: it may concern the product itself, a dose, an indication, coding, or the plan's off-label criteria.
How to appeal it
Off-label-use denials win when the appeal documents: (1) the FDA-approved indication and how the patient's use relates; (2) the off-label use is supported by peer-reviewed literature; (3) the off-label use is recognised by a major compendium (NCCN, DRUGDEX, AHFS-DI, Clinical Pharmacology) — federal law requires Medicare and Medicaid to recognise compendium-supported off-label use, and many commercial plans follow the same standard; (4) the off-label use is consistent with the relevant specialty-society guideline. The appeal cites the compendium entry by name.
Frequently asked questions
What does “drug not FDA approved” mean?
A not-FDA-approved denial (which may be associated with CARC 114 or 188) means the plan classified the drug, dose, or requested indication as outside the approval basis it applied. Verify the exact reason: it may concern the product itself, a dose, an indication, coding, or the plan's off-label criteria.
How do I appeal a 'not fda-approved' denials?
Off-label-use denials win when the appeal documents: (1) the FDA-approved indication and how the patient's use relates; (2) the off-label use is supported by peer-reviewed literature; (3) the off-label use is recognised by a major compendium (NCCN, DRUGDEX, AHFS-DI, Clinical Pharmacology) — federal law requires Medicare and Medicaid to recognise compendium-supported off-label use, and many commercial plans follow the same standard; (4) the off-label use is consistent with the relevant specialty-society guideline. The appeal cites the compendium entry by name.
Related
- CARC 55 — Procedure/treatment/drug is deemed experimental/investigatio…The carrier classified the treatment as experimental. Appealable when FDA-approved, peer-reviewed, o
- CARC 114 — Procedure/product not approved by the FDA.Procedure/product not approved by the FDA.
- CARC 188 — This product/procedure is only covered when used according t…This product/procedure is only covered when used according to FDA recommendations.
- ERISA §503ERISA §503 is the foundational federal appeal-rights statute for the ~135 million Americans on emplo
- ACA §2719 (PHSA §2719)ACA §2719 guarantees every non-grandfathered group + individual health plan a standardised internal
- Cancer treatmentsChemo, immunotherapy, CAR-T, proton, PET, off-label per NCCN
- Specialty biologicsHumira, Enbrel, Stelara, Skyrizi, Cosentyx, Rinvoq, Dupixent
- Rare disease — ERT, substrate reduction, gene therapyPompe, Fabry, Gaucher, MPS, Batten, NPC, PKU
- 'Duplicate therapy' denialsThe plan flagged your medication as duplicating another drug you're already taking. Appealable when
- 'Experimental / investigational' denialsThe plan called the treatment experimental. Often misapplied — and reversible by citing FDA approval
- 'Not medically necessary' denialsThe single most common appealable denial. The insurer says the treatment isn't medically necessary b
- 'Prior authorization required' denialsThe service required pre-approval that wasn't obtained. Appealable when the auth was attempted, when
Appeal a 'not fda-approved' denials denial
Upload the denial notice. DenialHelp helps verify the reason, organize source-linked evidence, and prepare a treating-clinician-reviewable package. Price and refund terms are shown before payment.
Get started →Contact: hello@denialhelp.com